| Gastrointestinal Stromal Tumors
Sutent vs Qinlock
Side-by-side clinical, coverage, and cost comparison for gastrointestinal stromal tumors.Deep comparison between: Sutent vs Qinlock with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQinlock has a higher rate of injection site reactions vs Sutent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qinlock but not Sutent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sutent
Qinlock
At A Glance
Oral
Daily
Multi-targeted RTK inhibitor
Oral
Daily
KIT/PDGFRA kinase inhibitor
Indications
- Gastrointestinal Stromal Tumors
- Renal Cell Carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
- Gastrointestinal Stromal Tumors
Dosing
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma 50 mg orally once daily on Schedule 4/2 (4 weeks on, 2 weeks off); adjuvant RCC limited to a maximum of nine 6-week cycles.
Well Differentiated Pancreatic Endocrine Neoplasm 37.5 mg orally once daily until disease progression or unacceptable toxicity.
Gastrointestinal Stromal Tumors 150 mg orally once daily with or without food until disease progression or unacceptable toxicity; tablets should be swallowed whole.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, thrombocytopenia.
Serious Hepatotoxicity, cardiovascular events, QT interval prolongation and Torsade de Pointes, hemorrhagic events, tumor lysis syndrome, thrombotic microangiopathy, proteinuria, dermatologic toxicities, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypoglycemia, osteonecrosis of the jaw, impaired wound healing.
Postmarketing Hemorrhage associated with thrombocytopenia, esophagitis, acalculous cholecystitis, hypersensitivity reactions including angioedema, serious infection, fistula formation, myopathy/rhabdomyolysis, renal impairment/failure, pulmonary embolism, pleural effusion, pyoderma gangrenosum, arterial aneurysms/dissections/rupture, arterial thromboembolic events.
Most common (>=20%) Alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, vomiting
Serious Abdominal pain, anemia, nausea, vomiting
Pharmacology
Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) including PDGFRalpha/beta, VEGFR1/2/3, KIT, FLT3, CSF-1R, and RET, which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer.
Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations, and also inhibits PDGFRB, TIE2, VEGFR2, and BRAF in vitro.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sutent
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Qinlock
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Sutent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Qinlock
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Sutent
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Qinlock
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Sutent Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Gastrointestinal Stromal Tumors (GIST) - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SutentView full Sutent profile
QinlockView full Qinlock profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.